Targeting TET Enzymes for Blood Cancers
Official title: Targeting TET DNA Dioxygenases as Therapeutic Principle in Myeloid Neoplasms
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11123910 · Data updated 2026-11-12
This research explores new ways to treat blood cancers like myelodysplastic syndromes (MDS) by focusing on specific enzymes called TET, which play a role in how these diseases develop.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 1, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $608,324 |
| NIH project number | 5R01CA257544-05 |
| Project ID | NIH-11123910 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with myeloid neoplasms, especially those with TET2 mutations, could potentially benefit from future treatments developed from this research.
✕Less likely to help
Patients without myeloid neoplasms or related hematologic malignancies may not directly benefit from this specific research.
What this research studies
TET enzymes are crucial for healthy cell function, particularly in how our DNA is regulated. Many individuals with blood cancers, including MDS, have changes in one of these enzymes, known as TET2. These changes can contribute to the early stages of blood disorders and even more aggressive forms of cancer. This project aims to understand precisely how these TET enzymes work and how their alterations lead to blood cancers. By gaining this understanding, we hope to discover new treatment strategies that specifically target these enzymes to stop the disease from progressing or potentially prevent it.
Why it matters
Potential benefit: If successful, this research could lead to new medications or therapies for patients with myeloid neoplasms, potentially improving treatment outcomes or preventing disease progression.
How similar studies have gone: Some related approaches targeting similar cellular pathways have shown promise in other conditions, and early findings in mouse models support this direction.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Maciejewski, Jaroslaw P. — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Maciejewski, Jaroslaw P.
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.